Comparative Pharmacology
Head-to-head clinical analysis: COTRIM D S versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COTRIM D S versus XIMINO.
COTRIM D.S. vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COTRIM D.S. is a combination of sulfamethoxazole, a competitive inhibitor of dihydropteroate synthase, and trimethoprim, a reversible inhibitor of dihydrofolate reductase. This sequential blockade of folate synthesis leads to bactericidal activity.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
160 mg trimethoprim / 800 mg sulfamethoxazole (one double-strength tablet) orally every 12 hours.
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (normal renal function). Trimethoprim: 8-11 hours. Both are prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: >24 hours). Clinical context: dosing interval is typically 12 hours; dose adjustment required if CrCl <30 mL/min.
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Sulfamethoxazole: ~20% unchanged in urine, remainder as acetylated and glucuronide metabolites. Trimethoprim: ~50-80% unchanged in urine, remainder as oxidative metabolites. Both undergo renal excretion via glomerular filtration and tubular secretion. Total renal elimination: 70-90% of dose combined. Biliary/fecal: <10%.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category C
Category C
Antibiotic
Antibiotic